The presence of thrombin-induced fibrinogen derivatives in the blood is considered by some authors to be a sign of hypercoagulability of the plasma. '-6 Fibrin monomers are known to form complexes with fibrinogen and fibrinogen degradation products (FDP/fdp), giving rise to high molecular weight complexes which are initially soluble. 2 7 When such complex formation occurs in the blood, a condition tentatively termed fibrinaemia is present.8 These complexes may be cleared by the reticuloendothelial system (RES) or deposited either diffusely (diffuse intravascular coagulation) or locally (local thrombosis).9-11 Fibrin monomers can be detected by several laboratory methods which vary in laboriousness and sensitivity.1 The clinical usefulness of a laboratory test in large numbers of patients is improved when, while remaining reliable, it is easy to perform. The ethanol gelation test (EGT) for the detection of circulating fibrin monomers, introduced by Godal and Abildgard,' fulfills these two criteria; however its sensitivity is limited because it only becomes positive when 2-4-3-8 % plasma fibrinogen is circulating in the form of fibrin monomers. 16 Using this test, fibrin monomer complexes have been detected in several diseases known to be associated with intravascular fibrin formation.3 812 Although one study lhas evaluated this test in a large number of hospital patients on admission,'17 the clinical signiAccepted for publication 6 October 1980 ficance of prolonged circulation of fibrin monomers remains obscure.
In order to define the clinical value of the EGT, we have performed this test in about one third of all patients admitted to our Department of Internal Medicine between 1970 and 1979. In a substantial number of these patients the test was frequently repeated to establish the effect of treatment and the course of the disease on the outcome of the test. The presence of a positive EGT was defined as fibrinaemia. We were especially interested in the significance of "chronic fibrinaemia" in its relation to thrombotic and haemorrhagic conditions and in the effect of antithrombotic drugs on the presence of fibrin monomers in vivo. In addition we have correlated the outcome of the EGT with fibrinogen levels and the level of FDP/fdp.
Materials and methods

PATIENTS
In the initial phase of the study, we performed the EGT in patients with all kinds of diseases admitted to the Department of Internal Medicine. In the last part of the study we were especially interested in patients with malignancy or suspected malignancy, thromboembolism, haemorrhagic diathesis, septicaemia, and liver disease.
The diagnosis of malignancy was in most cases confirmed by histological examination. Septicaemia was confirmed by positive blood cultures. The 468 group.bmj.com on November 7, 2017 -Published by http://jcp.bmj.com/ Downloaded from clinical diagnosis of liver cirrhosis was confirmed by liver biopsy. Venous thromboembolism was usually diagnosed by clinical examination but included in the study was a group of 37 patients with established venous thromboembolism, which has been described previously together with diagnostic criteria. 18 We performed the EGT in 3293 patients, 37-3 % of those admitted to our Department.
BLOOD SAMPLING
Blood was collected by venipuncture: nine volumes of venous blood were mixed as soon as possible with one volume of 3-8 % trisodium citrate solution. The plasma was separated from the cells by centrifugation for 10 min at 1260 g at room temperature.
THE ETHANOL GELATION TEST
The EGT was performed according to Godal and Abildgard.1 In brief: 0-5 ml plasma was mixed with 0-5 ml 50 % ethanol and was left undisturbed at room temperature for exactly 10 minutes. It was then examined for gel formation by gently tilting the tube. Only when clear gel formation occurred, was the test considered positive. When only precipitation or change of opacity occurred in the absence of gel formation, the test was considered to be negative.
Although the results of a single determination are included in the results, the final analysis only refers to those patients for whom the test was positive on at least two occasions, necessitated as a check against false positive tests arising from a technically poor venipuncture.
FIBRINOGEN
Fibrinogen was determined as described by Strengers and Asberg.19 Normal value: 200-400 mg/100 ml.
FIBRINOGEN/FIBRIN DEGRADATION
PRODUCTS (FDP/fdp) FDP/fdp were determined by the method described by Laurell.20 Four ml blood were collected into 0-04 ml aprotinine (Transylol: 100 000 KIU/ml) and kept at 37°C for 2 hours, after which it was centrifuged for 10 min at 1260g. One ml of the supernatant serum was incubated with 20 U thrombin at 37°C for 15 min and then centrifuged for 15 min at 1260 g. The samples were stored at -20°C until testing. All normal subjects had a level below 1-5 mg/100 ml serum.
THROMBIN
Thrombin (Topostasin, Roche, Basle) was dissolved in saline (0-9 % NaCI) to a final concentration of 500 U/ml. Freshly prepared thrombin solution was used.
Results
Between 1970 and 1979 we performed the EGT on 6782 occasions in a total of 3293 patients with various diseases. In 149 of these (4 5 %) the test was positive at least once. Since the detection of a positive EGT prompted further investigations, it was possible to determine the duration of this abnormality. As is shown in Table 1 the test was positive for only one day in 83 patients, for two to five days in 21 patients and for more than five days in 45 patients. The longest positive EGT was followed for five years. (Table 3) .
THROMBOHAEMORRHAGIC CONDITIONS, FDP/fdp AND FIBRINAEMIA Thirty-seven patients had established venous thromboembolism, but without malignancy, fibrinaemia was detected in only two of these and this was short-term and never a chronic phenomenon.
The most prominent clinical symptom of chronic fibrinaemia was venous thromboembolism (Tables 2  and 4 ). In patients with malignancy and chronic fibrinaemia, a haemorrhagic diathesis was present only occasionally and in about half of such patients thrombohaemorrhagic symptoms were absent (Table Neither of these conditions 13 of these patients. Three of these showed clinical thromboembolism (5-2 %). In the residual 58 patients the serum FDP/fdp level was 2 mg/100 ml or more and eight of these showed clinical thromboembolism (13-7%). Thirty-seven patients had established venous thromboembolism, but without malignancy, fibrinaemia was detected in only two of these and this was short-term and never a chronic phenomenon.
RELATION BETWEEN FIBRINOGEN,
FDP/fdp AND FIBRINAEMIA The distribution of fibrinaemia at various fibrinogen levels is shown in Table 5 . The majority of patients with fibrinaemia had a fibrinogen level between 50 and 500 mg/100 ml; at fibrinogen concentrations of more than 500 mg/100 ml the incidence of a positive EGT dropped. The level of FDP/fdp in serum exceeded 1P5 mg/100 ml and was more than 2 mg/100 ml in 97-3 % and 93% respectively of all patients with a positive EGT ( Table 6 ). The level of FDP/fdp in serum exceeded 1P5 mg/100 ml and was more than 2 mg/100 ml in 29% and 21 % respectively of all patients with a negative EGT (Table 6 ). High fibrinogen levels do not exclude the possibility of a negative ethanol gelation test. It has been reported that almost 50 0 of the patients in which the EGT is positive display an increased fibrinogen level (> 500 mg/100 mi).1617 This is not in agreement with our results.
The effect of anticoagulant treatment on fibrinaemia was not uniform. In all patients the EGT became negative upon heparin treatment although the dosage required varied widely. It appears most logical to relate the effect of heparin to its inhibitory action on activated coagulation factors (Xa) and thrombin through antithrombin Ill. When instead of heparin, coumarin derivatives were used, chronic fibrinaemia persisted despite adequate prolongation of the prothrombin time.
